A Tetravalent Bispecific T-Cell Engager with Optimized Efficacy & Safety Profile for Oncology & Autoimmune Indications
Time: 2:45 pm
day: Day 1
Details:
- Developing a tetravalent TCE platform FIT-Ig with reduced CRS
- Clinical validation of FIT-Ig based TCE for hematology and autoimmunity
- Optimizing a FIT-Ig based TCE for solid tumors
